Get started
Author

David Šulc

Observed names: D. Sulc, David Sulc
Institution: Krajská Zdravotní
ORCID: 0009-0006-9373-9841
Observed ORCID: 0009-0006-9373-9841
OpenAlex ID: A5055367757
Nationwide Implementation of Neoadjuvant Nivolumab-Based Chemo-Immunotherapy for Resectable NSCLC: Surgical Outcomes from a Prospective Multicenter Study
2026 · Jiri Vachtenheim Jr, Fernando Casas-Mendez, et al. · Annals of Surgical Oncology · 2
PDF
Prognostic Biomarkers for Anti‐ PD ‐1 Monoclonal Antibodies in the First Line Treatment of Advanced Melanoma
2025 · Marek Pásek, Emanuel Marques, et al. · International Journal of Dermatology · 2
PDF
Chemotherapy as an optimal treatment option after failure of immunotherapy and targeted therapy in advanced and metastatic melanoma
2024 · David Šulc · Klinicka onkologie · 2
PDF
Neoadjuvant targeted therapy in melanoma: Long-term effect of systemic therapy with encorafenib + binimetinib with histologically confirmed pCR in young female with BRAFmut melanoma with large solitary liver metastasis
2026 · D. Sulc, A. Chodacki, et al. · EJC Skin Cancer
A case of fairly advanced metastatic BRAF-mutated malignant melanoma treated with pembrolizumab with an excellent therapeutic response
2020 · David Šulc · Onkologie
PDF
Systemic treatment for metastatic uveal melanoma with anti-PD-1 antibodies
2020 · David Šulc · Onkologie
PDF
Pembrolizumab in II. line therapy of metastatic BRAF-mutated malignant melanoma Case report of long-term remission after vemurafenib treatment failure
2017 · David Šulc, Jana Pukyová, et al. · Dermatologie pro praxi
PDF
Triple negative breast cancer treated with bevacizumab
2016 · Jana Pukyová, David Šulc, et al. · Onkologie
Works count: 8
Citation count: 6
H-index: 2
I10-index:
Year
Topic
Type